Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
HTG Molecular Diagnostics logo — HTG is focused on advancing precision medicine

HTG Molecular Diagnostics

HTG is focused on advancing precision medicine

Founded 1997 United States Tucson, United States 33 employees Post Ipo Equity Total: $106.51M Biotechnology, Health Care +1

General Information

Company Name HTG Molecular Diagnostics
Founded Year 1997
Location United States Tucson, United States +1
Founders / Decision Makers
Team member Team member Team member
Employees 33
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when HTG Molecular Diagnostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About HTG Molecular Diagnostics

HTG Molecular Diagnostics is a biotechnology startup headquartered in the United States. Since its founding in 1997, the company has been dedicated to advancing precision medicine. Their mission, encapsulated in the slogan "HTG is focused on advancing precision medicine," resonates with the growing trend of personalized healthcare. HTG's approach involves harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics, and targeted therapeutics across various disease areas. With a track record spanning over a decade, HTG has established innovative partnerships with biopharma leaders and major academic institutes. This has led to the development of proprietary RNA platform technologies designed to enhance the effectiveness and efficiency of life science tools and diagnostics. HTG also aims to unlock a differentiated and disruptive approach to transformative drug discovery, positioning itself at the forefront of the rapidly evolving biotechnology landscape. In a recent significant development, HTG Molecular Diagnostics raised a $10.00M Post-IPO Equity investment on 21 December 2022. This injection of funds showcases the confidence investors have in HTG's vision and potential. As precision medicine continues to gain traction, HTG's innovative solutions and strategic partnerships bode well for its future growth and impact in the field.

Taxonomy: Precision Medicine, Transcriptome Profiling, Clinical Diagnostics, Therapeutics, Biopharma Partnerships, RNA Platform Technologies, Life Science Tools, Diagnostics, NGS-adapted Chemistry, HTG EdgeSeq Technology, Molecular Profiling, Sequencing, Gene Expression, Companion Diagnostics, Molecular-based Technology

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 21 Dec 2022
Post-IPO Equity •••••• - 18 Mar 2022
Post-IPO Equity •••••• - 03 Oct 2019
Debt Financing •••••• 2 •••• •••• 29 Aug 2014
Series E •••••• - 13 Feb 2014

View All 14 Funding Rounds

HTG Molecular Diagnostics Alternatives & Competitors

HTG Molecular Diagnostics vs
GeneCast Biotechnology Co., Ltd.
GeneCast Biotechnology Co., Ltd. China

Founded in November, 2014, Genecast (Beijing) Biotechnology Co. is located in HealthWork (Beijing) I...

Series E
21 employees
Biotechnology, Health Care
Compare HTG Molecular Diagnostics vs GeneCast Biotechnology Co., Ltd.
HTG Molecular Diagnostics vs
ATONARP
ATONARP Japan

Unlocking Molecular Insights

Series D
38 employees
Analytics, Care Economy
Compare HTG Molecular Diagnostics vs ATONARP
HTG Molecular Diagnostics vs
QuantumCyte, Inc.
QuantumCyte, Inc. United States

Sample in. Clarity out.

Unknown
15 employees
Biotechnology, Life Sciences
Compare HTG Molecular Diagnostics vs QuantumCyte, Inc.

FAQ About HTG Molecular Diagnostics

HTG is focused on advancing precision medicine
HTG Molecular Diagnostics was founded in 1997.
HTG Molecular Diagnostics is headquartered in Tucson, United States.
HTG Molecular Diagnostics operates in the following industries: Biotechnology, Health Care, Life Sciences.
HTG Molecular Diagnostics has approximately 33 employees.
HTG Molecular Diagnostics has completed 14 funding rounds, raising a total of $106.51M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to HTG Molecular Diagnostics include GeneCast Biotechnology Co., Ltd., ATONARP, QuantumCyte, Inc., BillionToOne, SYSTAAQ Diagnostic Product Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HTG Molecular Diagnostics and GeneCast Biotechnology Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors HTG Molecular Diagnostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy